VYNE News and Press, VYNE Therapeutics Inc Com From 10/30/23

Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritis Following completion of recent financing, VYNE expects to initiate a Phase 1a SAD/MAD clinical trial in Q1 202...

BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...

Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events acros...

BRIDGEWATER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inf...

2023-08-14 09:32:28 ET VYNE Therapeutics press release ( NASDAQ: VYNE ): Q2 Non-GAAP EPS of -$2.82. Revenue of $0.14M (+7.7% Y/Y) beats by $0.09M . For further details see: VYNE Therapeutics Non-GAAP EPS of -$2.82, revenue of $0.14M beats by $0.09M

Anticipate announcing preliminary Phase 1b safety and efficacy data for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in Q3 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in anticipation of indication s...

BRIDGEWATER, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflam...

2023-05-15 08:25:29 ET GSI Technology ( GSIT ) +210% . ARS Pharmaceuticals ( SPRY ) +78% . ImmunoPrecise Antibodies  ( IPA ) +39% . AirSculpt Technologies ( AIRS ) +37% . Meihua International Medical Technologies ( MHUA ) +37% ...

2023-05-11 17:00:02 ET VYNE Therapeutics press release ( NASDAQ: VYNE ): Q1 GAAP EPS of -$1.74 beats by $0.87 . Revenue of $0.1M (-44.4% Y/Y). Research and development expenses . VYNE's research and development expenses for the quarter ended March 31, 2023 were...

Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in ...